March 27, 2025
Septerna
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Seaport Therapeutics
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
February 24, 2025
Synnovation Therapeutics
Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors
February 21, 2025
Seaport Therapeutics
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies